



Natural Compounds Activities against SARS-CoV-2 Mpro through Bioinformatics Approaches for Development of Antivirus Candidates

Taufik Muhammad Fakhri

Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Islam Bandung, Bandung, Indonesia

Corresponding author: taufikmuhammadf@gmail.com

<https://doi.org/10.14710/jksa.24.5.170-176>



Article Info

Article history:

Received: 19th May 2020

Revised: 28th June 2021

Accepted: 26th July 2021

Online: 31st July 2021

Keywords:

COVID-19; SARS-CoV-2 Mpro; ACE-2; natural compounds; bioinformatics study

Abstract

Coronavirus infection (COVID-19) caused by SARS-CoV-2 appears as a pandemic that has spread to almost all countries in the world. Antiviral therapy using natural compounds is one alternative approach to overcome this infectious disease. The therapeutic mechanism is proven effective against the main protease (Mpro) of SARS-CoV-2. This research aims to perform bioinformatics studies, including ligand-docking simulations and protein-protein docking simulations, to identify, evaluate, and explore five compounds' activity on SARS-CoV-2 Mpro and their effects against Angiotensin-Converting Enzyme 2 (ACE-2). Protein-ligand docking simulations show kaempferol, flavonol, and their glycosides (Afzelin and Juglanin) and other flavonoids (Quercetin, Naringenin, and Genistein) have a high affinity towards SARS-CoV-2 Mpro. These results were then confirmed using protein-protein docking simulations to observe the ability of five compounds to prevent the attachment of ACE-2 to the active site. Based on the results of the bioinformatics studies, Quercetin has the best affinity, with a binding free energy value of -33.18 kJ/mol. The five compounds are predicted to be able to interact strongly with SARS-CoV-2. The results in this research are useful for further studies in the development of novel anti-infective drugs for COVID-19 that target SARS-CoV-2 Mpro.

1. Introduction

The 2019 coronavirus infection (COVID-19) was first discovered in Wuhan City, Hubei Province, China, and has now become a pandemic due to its rapid spread to 25 countries worldwide [1]. For this incident, the World Health Organization (WHO) announced a global health emergency on 30 January 2020 [2, 3]. In its first emergency meeting, WHO estimated the COVID-19 mortality rate to be around 4% [4]. Collaborative efforts by researchers worldwide are underway to understand the characteristics of the virus that causes this disease, namely SARS-CoV-2 (originally named 2019-nCoV), and develop effective drug candidates to control and prevent it [5].

The SARS-CoV-2 genome consists of ~30,000 nucleotides and functions to encode two overlapping polyproteins, namely pp1a and pp1ab. These polyproteins

are needed for virus replication and transcription [6]. Functional polypeptides are released from polyproteins through proteolytic processes involving the main protease (Mpro) [7]. Preliminary studies also show that SARS-CoV-2 has structural similarities to SARS-CoV based on complete phylogenetic analysis of the genome [8, 9]. Besides, both interact directly with Angiotensin-Converting Enzyme 2 (ACE-2) to enter the target cell [10].

ACE-2 can mediate the entry of SARS-CoV-2 into cells so that it acts as a functional receptor for coronavirus. SARS-CoV-2 involves ACE-2 with an affinity comparable to SARS-CoV [11]. The tight bonding in ACE-2 can explain part of the efficient transmission of SARS-CoV-2 in humans, as happened in SARS-CoV [12]. Therefore, the inhibition of SARS-CoV-2 attachment to ACE-2 is a pathway in developing inhibitors for COVID-19 infectious diseases.

Several herbal antiviral agents have been developed to disrupt the viral life cycle [13]. At the beginning of the first appearance of SARS in 2002–2003, around 50% of patients in mainland China were successfully treated using herbal medicines [13]. Kaempferol flavonols and their glycosides (Afzelin and Juglanin), as well as other flavonoids (Quercetin, Naringenin, and Genistein), have been reported to have inhibitory activity against the main protease (Mpro) SARS-CoV or viral replication [14]. Interestingly, all of these compounds are contained in natural Indonesian herbs, such as Afzelin (from *Annona purpurea*, *Piper umbellatum*, *Zingiber zerumbet*, *Nymphaea odorata*, and *Ginkgo biloba*) [15], Juglanin (from *Polygonum aviculare*) [16, 17], Quercetin (from *Camellia sinensis*, *Moringa oleifera*, *Centella asiatica*, *Apium graveolens*, and *Coriandrum sativum*) [18], Naringenin (Citrus species, *Ficus carica*) [19], Genistein (*Flemingia vestita*, Rutaceae family, *Fortunella obovata*, *Erythrina variegata*, *Millettia reticulata*, *Tetracera scandens*, *Genista sessilifolia*, and *Amaryllidaceae species*) [20].

Nowadays, the need to design effective antiviral candidates against SARS-CoV-2 is increasing. This research aims to observe the molecular interactions

between several natural compounds in the main protease (Mpro) of SARS-CoV-2 and their effects in inhibiting the binding of ACE-2. Bioinformatics approaches through ligand-protein, and protein-protein docking simulations can be used to identify, evaluate, and characterize potential components of SARS-COV-2 [21]. Specifically, SARS-CoV-2 Mpro is considered a target because it is a major part of forming the characteristics of the coronavirus. Thus, through this research, it is expected to obtain the structure of reference compounds to treat COVID-19 infections.

2. Methodology

2.1. Macromolecule Preparation

Macromolecules used in this research were the main proteases (Mpro) of SARS-CoV-2, and Angiotensin-Converting Enzyme (ACE-2) obtained from Protein Data Bank (<http://www.rcsb.org/pdb>) with PDB ID 6LU7 [22] and 2AJF [23], respectively. The preparation of these two macromolecules was carried out by removing water molecules and native ligands, adding polar hydrogen atoms, and calculating the Kollman charge using AutoDock 4.2 with MGLTools 1.5.6 [24, 25].




Figure 1. Two-dimensional structure and physicochemical properties of ligands

2.2. Ligand Preparation

The ligands used in this research were Kaempferol flavonol and their glycosides (Afzelin and Juglanin), as well as other flavonoids (Quercetin, Naringenin, and Genistein), obtained from PubChem

(<https://pubchem.ncbi.nlm.nih.gov/>) (Figure 1). The ligand structure was optimized using Quantum ESPRESSO 6.6 with Density Functional Theory (DFT) method based on the 3-21G basis set [26, 27]. Finally, all ligands were prepared by adding a hydrogen atom and calculating the Gasteiger charge using AutoDock 4.2 with

MGLTools 1.5.6 [24, 25]. Structural preparation aims to optimize compounds for use as input in ligand-protein docking simulations.

2.3. Identification of Ligand-Binding Sites in SARS-CoV-2 Mpro

Macromolecules of SARS-CoV-2 Mpro that have been prepared are then identified, evaluated, and explored binding sites that are most responsible for biological activity using BIOVIA Discovery Studio 2020 [28]. All amino acids that occur around the native ligand within a spherical radius distance set are prepared for the location of protein-ligand binding in ligand-protein docking simulations.

2.4. Ligand-Protein Docking Simulations

The ligand-protein docking simulations were performed using AutoDock 4.2 with MGLTools 1.5.6 [24, 25]. All ligand molecules for this simulation were added hydrogen atoms and partial charges data from the Density Functional Theory (DFT) calculations. Simulations were created by a grid box $64 \times 60 \times 60$ points with 0.375 \AA spacing to cover the binding cavity of the target [29]. The Lamarckian Genetic Algorithm with 100 conformations was chosen for each simulation, and other docking parameters were set as default. Observation of the docking simulation results was performed using Discovery Studio 2020 [28].

2.5. Protein-Protein Docking Simulations

Protein-protein docking simulations were performed using PatchDock for five complexes from the results of ligand-protein docking simulations in SARS-CoV-2 Mpro [30]. The simulations were accomplished against active sites of the Angiotensin-Converting Enzyme (ACE-2) macromolecules, including Gln24, Lys31, His34, Glu37, Asp38, Tyr41, Gln42, Met82, Tyr83, Glu329, Asn330, Lys353, and Gly354. The default clustering RMSD 4.0 \AA was used, and the complex type was chosen to be a protein-protein. The Connolly dot surface representation of the molecules into different components such as convex, concave, and flat patches were generated through the PatchDock algorithm. PatchDock was optimized, refined, reshuffled, and rescored the side chain interface of the top 10 candidate solutions. It also amends the orientation of the relative molecules by confining the flexibility to the side-chains of the interacting surface and allow the movements of a small rigid body. The conformation of the systems was verified by visualization analysis with Discovery Studio 2020 [28].

3. Results and Discussions

3.1. Ligand-Protein Docking Simulations

Kaempferol flavonol and their glycosides (Afzelin and Juglanin) and other flavonoids (Quercetin, Naringenin, and Genistein) were docked into SARS-CoV-2 Mpro as a macromolecular target. Moreover, molecular docking of natural ligands was also performed as a comparison against the five tested ligands. All complexes from the results from protein-ligand docking were selected for further studies using protein-protein docking methods against ACE-2. Five ligands have a larger negative binding free energy than natural ligands to the active site of SARS-CoV-2 Mpro (Table 1). This phenomenon shows a promising sign that these ligands have an excellent affinity to the target macromolecules. Quercetin has the best binding at the active site of SARS-CoV-2, with a binding free energy value of -33.18 kJ/mol better than other ligands.

Table 1. Binding Free Energy of Ligands to SARS-CoV-2 Mpro

| Ligand | Binding Free Energy (kJ/mol) |
|---------------|------------------------------|
| Native ligand | -18.58 |
| Afzelin | -27.49 |
| Juglanin | -32.05 |
| Quercetin | -33.18 |
| Naringenin | -30.46 |
| Genistein | -29.33 |

All the ligands have related interactions against SARS-CoV-2 Mpro (indicated by the binding energy value, which is almost similar) (Figure 2). In general, the interaction of each ligand with SARS-CoV-2 Mpro was dominated by ten hydrogen bonds (with Phe140, Gly143, His163, His164, Met165, Glu166, His172, Gln189, and Thr190) and seven hydrophobic interactions (with His41, Met49, Leu141, Asn142, Met165, Pro168, and Ala191). Interestingly, Quercetin, as the ligand with the best binding free energy, has more molecular interactions than natural ligands. Quercetin can form twelve interactions, including seven hydrogen bonds (with Gln192, Thr190, Thr190, Glu166, His164, Tyr54, and Asp187) and five hydrophobic interactions (with His41, Met165, Met165, Met165, and Pro168). Meanwhile, natural ligands could only form ten interactions consisting of seven hydrogen bonds (with Asn142, Phe140, Glu166, Gln189, Thr190, Asn142, and Leu141) and three hydrophobic interactions (with Met165, Pro168, and Ala191).

complex against ACE-2 [33]. Interestingly, Quercetin effectively inhibited the attachment of ACE-2 to the binding area of SARS-CoV-2 Mpro because it has the largest positive ACE, with a score of 1684.48 kJ/mol. Most inhibitors work by binding firmly to the active sites of the target receptor and competing with its native ligand, as well as stabilizing the structure of the receptor macromolecules and preventing the conformational changes needed to progress the signal further.




Figure 3. Protein-Protein Docking Pose of Quercetin Complexes (pink) against ACE-2 (blue)

Subsequent analysis was performed on the conformation of the Quercetin + SARS-CoV-2 Mpro complex with ACE-2 (Figure 3). Ten unfavorable bonds were formed, namely the amino acid residues Lys313, Val316, Val316, Ala387, Gln552, Gln552, Gln552, Phe555, and Pro321. Besides, other interactions that contribute include thirteen hydrogen bonds (with Arg306, Asp427, Glu310, Lys309, Thr548, Gln325, Thr548, Glu549, Asn546, Gly319, Gly319, Ser420, and Gly422), six hydrophobic interactions (with Lys313, Pro321, Ala387, Lys313, Pro321, and Phe555), and nine electrostatic interactions (with Arg306, Asp427, Asp427, Glu310, Glu310, Asp427, Arg306, Lys313, and Phe555). Eventually, it can be predicted that Quercetin is a potential candidate for SARS-CoV-2 Mpro inhibitor and can prevent attachment to ACE-2, which acts as an entry point into human cells.

4. Conclusion

Several compounds of kaempferol, flavonol, and glycoside derivatives (Afzelin and Juglanin) and other flavonoids (Quercetin, Naringenin, and Genistein) can bind stably against SARS-CoV-2 Mpro. However, Quercetin has the strongest interaction with the target macromolecular active site, with the binding free energy value of -33.18 kJ/mol. The five ligands are also able to inhibit the formation of interactions with ACE-2. Thus, the study results indicate that the compound can be

further developed as a SARS-CoV-2 Mpro inhibitor in COVID-19 infection therapy.

Acknowledgment

The authors thank the LPPM (Institute for Research and Community Service), Universitas Islam Bandung, for the research financially supported by the Special Research Grant Program 2020, No.039/B.04/LPPM/IV/2020.

References

- [1] Chen Wang, Peter W. Horby, Frederick G. Hayden, George F. Gao, A novel coronavirus outbreak of global health concern, *The Lancet*, 395, 10223, (2020), 470–473
[https://doi.org/10.1016/S0140-6736\(20\)30185-9](https://doi.org/10.1016/S0140-6736(20)30185-9)
- [2] Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, Li Zhang, Guohui Fan, Jiuyang Xu, Xiaoying Gu, Zhenshun Cheng, Ting Yu, Jiaan Xia, Yuan Wei, Wenjuan Wu, Xuelei Xie, Wen Yin, Hui Li, Min Liu, Yan Xiao, Hong Gao, Li Guo, Jungang Xie, Guangfa Wang, Rongmeng Jiang, Zhancheng Gao, Qi Jin, Jianwei Wang, Bin Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, *The Lancet*, 395, 10223, (2020), 497–506
[https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
- [3] David L. Heymann, Data sharing and outbreaks: best practice exemplified, *The Lancet*, 395, 10223, (2020), 469–470
[https://doi.org/10.1016/S0140-6736\(20\)30184-7](https://doi.org/10.1016/S0140-6736(20)30184-7)
- [4] Catrin Sohrabi, Zaid Alsafi, Niamh O'Neill, Mehdi Khan, Ahmed Kerwan, Ahmed Al-Jabir, Christos Iosifidis, Riaz Agha, World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19), *International Journal of Surgery*, 76, (2020), 71–76
<https://doi.org/10.1016/j.ijso.2020.02.034>
- [5] Peng Zhou, Xing-Lou Yang, Xian-Guang Wang, Ben Hu, Lei Zhang, Wei Zhang, Hao-Rui Si, Yan Zhu, Bei Li, Chao-Lin Huang, Hui-Dong Chen, Jing Chen, Yun Luo, Hua Guo, Ren-Di Jiang, Mei-Qin Liu, Ying Chen, Xu-Rui Shen, Xi Wang, Xiao-Shuang Zheng, Kai Zhao, Quan-Jiao Chen, Fei Deng, Lin-Lin Liu, Bing Yan, Fa-Xian Zhan, Yan-Yi Wang, Geng-Fu Xiao, Zheng-Li Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin, *Nature*, 579, 7798, (2020), 270–273
<https://doi.org/10.1038/s41586-020-2012-7>
- [6] Roujian Lu, Xiang Zhao, Juan Li, Peihua Niu, Bo Yang, Honglong Wu, Wenling Wang, Hao Song, Baoying Huang, Na Zhu, Yuhai Bi, Xuejun Ma, Faxian Zhan, Liang Wang, Tao Hu, Hong Zhou, Zhenhong Hu, Weimin Zhou, Li Zhao, Jing Chen, Yao Meng, Ji Wang, Yang Lin, Jianying Yuan, Zhihao Xie, Jinmin Ma, William J. Liu, Dayan Wang, Wenbo Xu, Edward C. Holmes, George F. Gao, Guizhen Wu, Weijun Chen, Weifeng Shi, Wenjie Tan, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, *The Lancet*, 395, 10224, (2020), 565–574
[https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)
- [7] Xing-Yi Ge, Jia-Lu Li, Xing-Lou Yang, Aleksei A. Chmura, Guangjian Zhu, Jonathan H. Epstein, Jonna K. Mazet, Ben Hu, Wei Zhang, Cheng Peng, Yu-Ji Zhang, Chu-Ming Luo, Bing Tan, Ning Wang, Yan

- Zhu, Gary Cramer, Shu-Yi Zhang, Lin-Fa Wang, Peter Daszak, Zheng-Li Shi, Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor, *Nature*, 503, 7477, (2013), 535–538 <https://doi.org/10.1038/nature12711>
- [8] Michael Letko, Andrea Marzi, Vincent Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses, *Nature Microbiology*, 5, 4, (2020), 562–569 <https://doi.org/10.1038/s41564-020-0688-y>
- [9] Yu Chen, Hui Cai, Ji Pan, an, Nian Xiang, Po Tien, Tero Ahola, Deyin Guo, Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase, *Proceedings of the National Academy of Sciences*, 106, 9, (2009), 3484 <https://doi.org/10.1073/pnas.0808790106>
- [10] Alexandra C. Walls, Young-Jun Park, M. Alejandra Tortorici, Abigail Wall, Andrew T. McGuire, David Veelsler, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, *Cell*, 181, 2, (2020), 281–292.e286 <https://doi.org/10.1016/j.cell.2020.02.058>
- [11] Alexandra C. Walls, Xiaoli Xiong, Young-Jun Park, M. Alejandra Tortorici, Joost Snijder, Joel Quispe, Elisabetta Cameroni, Robin Gopal, Mian Dai, Antonio Lanzavecchia, Maria Zambon, Félix A. Rey, Davide Corti, David Veelsler, Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion, *Cell*, 176, 5, (2019), 1026–1039.e1015 <https://doi.org/10.1016/j.cell.2018.12.028>
- [12] Jung-Eun Park, Kun Li, Arlene Barlan, Anthony R. Fehr, Stanley Perlman, Paul B. McCray, Tom Gallagher, Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism, *Proceedings of the National Academy of Sciences*, 113, 43, (2016), 12262 <https://doi.org/10.1073/pnas.1608147113>
- [13] Kai Wang, Shiqi Xie, Bing Sun, Viral proteins function as ion channels, *Biochimica et Biophysica Acta (BBA) - Biomembranes*, 1808, 2, (2011), 510–515 <https://doi.org/10.1016/j.bbamem.2010.05.006>
- [14] Silvia Schwarz, Kai Wang, Wenjing Yu, Bing Sun, Wolfgang Schwarz, Emodin inhibits current through SARS-associated coronavirus 3a protein, *Antiviral Research*, 90, 1, (2011), 64–69 <https://doi.org/10.1016/j.antiviral.2011.02.008>
- [15] Eva Rachmi, Basuki Bambang Purnomo, Agustina Tri Endharti, Loeki Enggar Fitri, Identification of afzelin potential targets in inhibiting triple-negative breast cancer cell migration using reverse docking, *Porto Biomedical Journal*, 5, 6, (2020), e095 <https://doi.org/10.1097/j.pbj.000000000000095>
- [16] Liang Chen, Ya-Qiong Xiong, Jing Xu, Ji-Peng Wang, Zi-Li Meng, Yong-Qing Hong, Juglanin inhibits lung cancer by regulation of apoptosis, ROS and autophagy induction, *Oncotarget*, 8, 55, (2017), 93878–93898 <https://doi.org/10.18632/oncotarget.21317>
- [17] Ze-Wu Dong, Yu-Fang Yuan, Juglanin suppresses fibrosis and inflammation response caused by LPS in acute lung injury, *International Journal of Molecular Medicine*, 41, 6, (2018), 3353–3365 <https://doi.org/10.3892/ijmm.2018.3554>
- [18] A. V. Anand David, R. Arulmoli, S. Parasuraman, Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid, *Pharmacognosy Reviews*, 10, 20, (2016), 84–89 <https://doi.org/10.4103/0973-7847.194044>
- [19] Bahare Salehi, Patrick Valere Tsouh Fokou, Mehdi Sharifi-Rad, Paolo Zucca, Raffaele Pezzani, Natália Martins, Javad Sharifi-Rad, The Therapeutic Potential of Naringenin: A Review of Clinical Trials, *Pharmaceuticals*, 12, 1, (2019), 11 <https://doi.org/10.3390/ph12010011>
- [20] V. Tandon, B. Das, Genistein: is the multifarious botanical a natural anthelmintic too?, *Journal of Parasitic Diseases*, 42, 2, (2018), 151–161 <https://doi.org/10.1007/s12639-018-0984-0>
- [21] Swatantra Kumar, Vimal K. Maurya, Anil K. Prasad, Madan L. B. Bhatt, Shailendra K. Saxena, Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV), *VirusDisease*, 31, 1, (2020), 13–21 <https://doi.org/10.1007/s13337-020-00571-5>
- [22] Zhenming Jin, Xiaoyu Du, Yechun Xu, Yongqiang Deng, Meiqin Liu, Yao Zhao, Bing Zhang, Xiaofeng Li, Leike Zhang, Chao Peng, Yinkai Duan, Jing Yu, Lin Wang, Kailin Yang, Fengjiang Liu, Rendu Jiang, Xinglou Yang, Tian You, Xiaoce Liu, Xiuna Yang, Fang Bai, Hong Liu, Xiang Liu, Luke W. Guddat, Wenqing Xu, Gengfu Xiao, Chengfeng Qin, Zhengli Shi, Hualiang Jiang, Zihao Rao, Haitao Yang, Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors, *Nature*, 582, 7811, (2020), 289–293 <https://doi.org/10.1038/s41586-020-2223-y>
- [23] Fang Li, Wenhui Li, Michael Farzan, Stephen C. Harrison, Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor, *Science*, 309, 5742, (2005), 1864 <https://doi.org/10.1126/science.1116480>
- [24] David S. Goodsell, Garrett M. Morris, Arthur J. Olson, Automated docking of flexible ligands: Applications of autodock, *Journal of Molecular Recognition*, 9, 1, (1996), 1–5 [https://doi.org/10.1002/\(SICI\)1099-1352\(199601\)9:1<1::AID-JMR241>3.0.CO;2-6](https://doi.org/10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6)
- [25] Garrett M. Morris, David S. Goodsell, Robert S. Halliday, Ruth Huey, William E. Hart, Richard K. Belew, Arthur J. Olson, Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function, *Journal of Computational Chemistry*, 19, 14, (1998), 1639–1662 [https://doi.org/10.1002/\(SICI\)1096-987X\(19981115\)19:14<1639::AID-JCC10>3.0.CO;2-B](https://doi.org/10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B)
- [26] Paolo Giannozzi, Stefano Baroni, Nicola Bonini, Matteo Calandra, Roberto Car, Carlo Cavazzoni, Davide Ceresoli, Guido L. Chiarotti, Matteo Cococcioni, Ismaila Dabo, Andrea Dal Corso, Stefano de Gironcoli, Stefano Fabris, Guido Fratesi, Ralph Gebauer, Uwe Gerstmann, Christos Gougoussis, Anton Kokalj, Michele Lazzeri, Layla Martin-Samos, Nicola Marzari, Francesco Mauri, Riccardo Mazzarello, Stefano Paolini, Alfredo Pasquarello, Lorenzo Paulatto, Carlo Sbraccia, Sandro Scandolo, Gabriele Sclauzero, Ari P. Seitsonen, Alexander Smogunov, Paolo Umari, Renata M. Wentzcovitch, QUANTUM ESPRESSO: a modular and open-source software project for quantum simulations of materials, *Journal of Physics: Condensed Matter*, 21, 39, (2009), 395502 <http://dx.doi.org/10.1088/0953-8984/21/39/395502>

- [27] Paolo Giannozzi, Oscar Baseggio, Pietro Bonfà, Davide Brunato, Roberto Car, Ivan Carnimeo, Carlo Cavazzoni, Stefano de Gironcoli, Pietro Delugas, Fabrizio Ferrari Ruffino, Andrea Ferretti, Nicola Marzari, Iurii Timrov, Andrea Urru, Stefano Baroni, Quantum ESPRESSO toward the exascale, *The Journal of Chemical Physics*, 152, 15, (2020), 154105 <https://doi.org/10.1063/5.0005082>
- [28] Devjani I. Banerjee, Tejas P. Gohil, Interaction of antimicrobial peptide with mycolyl transferase in *Mycobacterium tuberculosis*, *International Journal of Mycobacteriology*, 5, 1, (2016), 83-88 <https://doi.org/10.1016/j.ijmyco.2015.07.002>
- [29] Meshari Alazmi, Olaa Motwalli, In silico virtual screening, characterization, docking and molecular dynamics studies of crucial SARS-CoV-2 proteins, *Journal of Biomolecular Structure and Dynamics*, (2020), 1-11 <https://doi.org/10.1080/07391102.2020.1803965>
- [30] D. Sathya Prabhu, V. Devi Rajeswari, In Silico Docking Analysis of Bioactive Compounds from Chinese Medicine Jinqi Jiangtang Tablet (JQJT) using Patch Dock, *Journal of Chemical and Pharmaceutical Research*, 8, 5, (2016), 15-21
- [31] Dwi Syah Fitra Ramadhan, Taufik Muhammad Fakhri, Arfan Arfan, Activity Prediction of Bioactive Compounds Contained in *Etilingera elatior* Against the SARS-CoV-2 Main Protease: An In Silico Approach, *Borneo Journal of Pharmacy*, 3, 4, (2020), 235-242 <https://doi.org/10.33084/bjop.v3i4.1634>
- [32] F. Fitriyani, Taufik Muhammad Fakhri, Daryono Hadi Tjahjono, In Silico Studies of Green Tea Catechins Against HER-2 Receptor in Breast Cancer, *Current Trends in Biotechnology & Pharmacy*, 14, 5, (2020), 194-199 <https://doi.org/10.5530/ctbp.2020.4s.23>
- [33] Vijayakumar Veeraragavan, Radhakrishnan Narayanaswamy, Rameshkumar Chidambaram, Predicting the Biodegradability Nature of Imidazole and Its Derivatives by Modulating Two Histidine Degradation Enzymes (Urocanase and Formiminoglutamase) Activities, *Asian Journal of Pharmaceutical and Clinical Research*, 10, 11, (2017), 383-386 <https://doi.org/10.22159/ajpcr.2017.v10i11.20999>